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Abstract
Background: Sodium hyaluronate (SH) solution has been used for submucosal injection in endoscopic resection
to create a long-lasting submucosal fluid "cushion". Recently, we proved the usefulness and safety of 0.4% SH
solution in endoscopic resection for gastric mucosal tumors. To evaluate the usefulness of 0.4% SH as a
submucosal injection solution for colorectal endoscopic resection, we conducted an open-label clinical trial on
six referral hospitals in Japan.
Methods: A prospective multi-center open-label study was designed. A total of 41 patients with 5–20 mm
neoplastic lesions localized in the colorectal mucosa at six referral hospitals in Japan in a single year period from
December 2002 to November 2003 were enrolled and underwent endoscopic resection with SH. The usefulness
of 0.4% SH was assessed by the en bloc complete resection and the formation and maintenance of mucosal lesion-
lifting during endoscopic resection. Safety was evaluated by analyzing adverse events during the study period.
Results: The usefulness rate was high (82.5%; 33/40). The following secondary outcome measures were noted:
1) steepness of mucosal lesion-lifting, 75.0% (30/40); 2) intraoperative complications, 10.0% (4/40); 3) time
required for mucosal resection, 6.7 min; 4) volume of submucosal injection, 6.8 mL and 5) ease of mucosal
resection, 87.5% (35/40). Two adverse events of bleeding potentially related to 0.4% SH were reported.
Conclusion:  Using 0.4% SH solution enabled sufficient lifting of a colorectal intramucosal lesion during
endoscopic resection, reducing the need for additional injections and the risk of perforation. Therefore, 0.4% SH
may contribute to the reduction of complications and serve as a promising submucosal injection solution due to
its potentially superior safety in comparison to normal saline solution.
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Background
The incidence of colorectal neoplasm in Japan is high, and
the number of patients with colorectal neoplasm is stead-
ily increasing. The chances of treating colorectal mucosal
lesion with endoscopy have increased [1-3]. Depending
on techniques and equipment, endoscopic resection of
the colon includes polypectomy, endoscopic mucosal
resection (EMR) and endoscopic submucosal dissection
(ESD) in the colon. Focusing on the physiochemical prop-
erties of sodium hyaluronate (SH), Yamamoto et al. devel-
oped a technique known as EMR using sodium
hyaluronate (EMRSH), and reported that when SH was
injected into the submucosal layer during EMR, mucosal
lesions could be adequately lifted for a sufficient duration
to allow safe, reliable, and complete resection without SH
diffusion or absorption by the submucosal layer [4,5].
Recently, we proved the usefulness and safety of 0.4% SH
solution in endoscopic resection for gastric mucosal
tumors [6]. To evaluate the usefulness of 0.4% SH as a
submucosal injection solution for colorectal endoscopic
resection, we conducted an open-label clinical trial on six
referral hospitals in Japan.
Methods
Patient selection
The target population of the study was consecutive
patients who visited six referral hospitals in Japan from
December 2002 to November 2003 on an outpatient basis
for colorectal mucosal neoplasms that could be treated
endoscopically. All patients underwent confirmation
colonoscopy within 4 weeks before endoscopic resection.
If a patient had already undergone colonoscopy within 4
weeks before informed consent, the data for that colonos-
copy was used as part of the study data to avoid another
colonoscopy, thereby minimizing stressful procedures for
the patient. The present study was explained to those
meeting the following criteria, and informed consent was
obtained from 44 patients. Three patients were excluded
for meeting the exclusion criteria and the remaining 41
patients were enrolled.
Inclusion criteria consisted of the following: a neoplastic
lesion 5–20 mm in diameter localized to the colorectal
mucosa; indication for endoscopic resection; and patient
age between 20 and 80 years. We limited the size of the
neoplasms because the guidelines for the Japanese Society
for Cancer of the Colon and Rectum [7] state that neo-
plasms of ≤ 20 mm in diameter can be completely
resected en bloc.
Exclusion criteria included: 1) residual or recurrent lesion,
2) lesion accompanied by ulceration, 3) submucosal inva-
sion, 4) pacemaker, 5) advanced malignant neoplasm, 6)
history of hypersensitivity to SH, 7) systemic administra-
tion of an anticancer agent, 8) severe liver, kidney or car-
diovascular disease; 9) pregnancy or lactation, or women
who wished to become pregnant during the study and 10)
patients judged to be inappropriate for inclusion by a phy-
sician.
The present study was conducted in compliance with the
Helsinki Declaration and Good Clinical Practice (GCP).
The institutional review boards (IRB) of all of the partici-
pating institutions (the IRB of Shikoku Cancer Center, the
IRB of National Cancer Center Hospital, the IRB of Jichi
Medical University, the IRB of Tokyo University, and the
IRB of Saku General Hospital) approved all study proto-
cols. Written informed consent was obtained from all
patients.
Concomitant medication
For 7 days before and after endoscopic resection, the use
of anticoagulants and antiplatelets that can induce bleed-
ing during endoscopic resection or from the surgical
wound, or drugs contraindicated in the treatment of pep-
tic ulcer, were prohibited. During endoscopic resection,
the submucosal injection of agents that could affect the
assessment of 0.4% SH, such as saline, 3.7% hypertonic
saline, 50% glucose and 10% glycerol were prohibited.
Except for epinephrine and indigo carmine, nothing was
added to submucosal injection solutions. However, the
concentrations for epinephrine and indigo carmine were
not stipulated as a part of the protocol. Furthermore, med-
ication was allowed to treat coexisting disorders not
included in the above and which occurred ≥ 4 weeks
before endoscopic resection as well as adverse events that
occurred during the study.
Study device
A solution of 0.4% SH was prepared by dissolving SH
(manufactured by Seikagaku Corp, Tokyo, Japan) to a
concentration of 0.4% (w/v), the solution was then placed
in a 20 mL glass vial and stored at room temperature. The
upper limit of 0.4% SH submucosal injection was 40 mL,
which is one-tenth of the nontoxic level with intraperito-
neal administration, and an appropriate amount was used
in each patient.
Study design
The present study involved six referral hospitals in Japan.
Patients who satisfied the inclusion criteria underwent
endoscopic resection. The primary outcome measure was
assessed by comprehensively evaluating en bloc complete
resection (en bloc resection with a histopathologically neg-
ative resection margin) and the lifting and maintaining of
a mucosal lesion during endoscopic resection (as the
number of additional injections required due to loss of
mucosal lesion-lifting) (Table 1). Usefulness rate was
defined as the percentage of en bloc complete resections
that required an additional injection number of 0 or 1.BMC Gastroenterology 2009, 9:1 http://www.biomedcentral.com/1471-230X/9/1
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Secondary outcome measures included 1) steepness to
which the lesion could be lifted using the solution
injected into the submucosal layer (steep: the lesion is ele-
vated vertically toward the lumen side to form a tall bulge,
mild: the lesion is dispersed laterally to form a shallow
bulge, non-lifted, not evaluable), 2) presence or absence
of bleeding, perforation and other intraoperative acciden-
tal events, 3) time required for mucosal resection, 4) sub-
mucosal injection volume, and 5) ease of mucosal
resection using submucosal injection (excellent, good,
moderate, poor). An adequately lifted lesion refers to a
highly lifted and protruding lesion that appears to push
the mucosa vertically into the lumen. In relation to the
average difficulty of a typical endoscopic resection (mod-
erate), the ease of mucosal resection was assessed in terms
of the extent to which the procedure was simplified using
0.4% SH compared with the conventional technique
using normal saline. Safety was analyzed in all patients
who underwent endoscopic resection by recording all
adverse events that were assessed as having potential
causal relationships. In addition, we defined serious
adverse events as those events that led to: death, life-
threatening conditions, notable disability, prolonged hos-
pital stay, or a requirement of hospitalization for therapy.
The patients were followed until adverse events either dis-
sipated or returned to pre-endoscopic resection levels. The
feasibility of 0.4% SH performance was assessed based on
usefulness and safety. Other investigated items included
biopsy diagnosis, pre- and postoperative endoscopic find-
ings, histopathological diagnosis, clinical laboratory tests,
and vital signs. These items were assessed as specified in
the study protocol. Taking into account the time for
wound healing following endoscopic resection, the study
period was 8 weeks during which recurrence, residual neo-
plastic tissue and wound healing at the site of resection
were ascertained [8,9]. In addition, although endoscopic
resection methods can be classified as EMR with mucosal
incision, conventional EMR and ESD, the choice of
approach was left to the discretion of the physicians at
each facility. Specifically, procedures involving snare
resection of the mucosal layer were classified as conven-
tional EMR, those involving snare resection following
mucosal incision were classified as EMR with mucosal
incision, and those involving dissection of the submu-
cosal layer following mucosal incision were classified as
ESD. ESD uses devices such as an insulation-tipped elec-
trosurgical (IT) knife [10], hook knife [11], flex knife
[12,13] or needle knife in combination with a small-cal-
iber tip transparent hood (ST hood) [14,15].
Statistical analysis and outcomes
As a general rule, the full analysis set (FAS) comprised all
patients who underwent endoscopic resection. All analy-
ses were performed using SAS software (SAS Institute,
Cary, North Carolina, USA). Intergroup comparisons
were conducted as follows.
Usefulness and safety were described by calculating 95%
confidence intervals using the binomial method. Values
of p < 0.05 were considered statistically significant. The
Wilcoxon two-sample test for continuous outcomes and
Fisher's exact test for binary outcomes were used. For clin-
ical laboratory test findings, the McNemar test was used to
assess changes before and after endoscopic resection.
Sample size
Endoscopic resection was clinically assessed based on en
bloc complete resection as determined by histopathologi-
cal analysis of the neoplastic lesions. The reported rate of
en bloc complete resection with normal saline as the sub-
mucosal injection solution is 72.9–85% [16-18]. From
this, when the rate of en bloc complete resection for the
0.4% SH was set at 90%, a sample size of 35 patients was
required in order to meet the hypothesized rate of 90%
resection with a 95% confidence interval of the length ±
10%. The established target number of patients for 0.4%
SH, allowing for potential dropouts, was 42.
Results
The FAS comprised 40 patients, because one patient met
the exclusion criteria. We analyzed the safety in all 41
patients. Fourteen patients (34.1%: 14/41) had 0.2 mL–
1.0 mL indigo carmine added to 0.4% SH. Fourteen
patients (34.1%: 14/41) had 0.1 mL–1.0 mL epinephrine
added to 0.4% SH. The final concentration of SH was
from 0.38% to 0.4%. Figure 1 shows the flowchart for the
study. Six patients were judged as having an incomplete
resection. Two patients did not have safe vertical and lat-
eral margin because of multifragment resections
(although one additional patient had a multifragment
resection, the patient was judged to have had a complete
resection because all of the neoplasm was contained in
Table 1: Primary outcome measure
Complete en bloc resection Complete Complete Complete Incomplete or Not evaluable
Additional count 0 1 2≤ -
Total evaluation† Excellent Good Moderate Poor
† Total evaluation of primary outcome measure was assessed by comprehensively evaluating complete en bloc resection and the number of 
additional injections during endoscopic resection. The primary outcome measure (usefulness rate) was defined as the percentage of excellent or 
good outcomes according to the criteria noted above.BMC Gastroenterology 2009, 9:1 http://www.biomedcentral.com/1471-230X/9/1
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one fragment). In the other four patients, the margin of
the fragment was positive for tumor or the lateral margin
of the lesion could not be evaluated histologically because
of the effects of the electrosurgical current or mechanical
damage. Demographic characteristics of the 40 patients at
baseline did not reveal differences in age, sex, histological
type, or neoplasm size (Table 2).
Conventional EMR comprised most of the endoscopic
resections (77.5%; 31/40) performed in the present study
(Table 3). Histological examination confirmed that all
resected tumors were intramucosal. Adenoma was diag-
nosed in 32 of the 40 patients (80%).
Clinical usefulness
Table 4 shows the assessment results. The primary out-
come measure was analyzed by comprehensively evaluat-
ing en bloc complete resection and additional injections
due to a loss in mucosal lesion-lifting (Table 1). The use-
fulness rate for the 0.4% SH was 82.5% (33/40). The rate
of endoscopic resection completion was favorable at all
institutions. Only one patient required an additional
injection due to the loss of mucosal lesion-lifting; none of
the other cases (39/40) required additional injections
(Table 4). The mean (SD) of additional injections was 0.1
(± 0.3). We evaluated secondary outcome measures as fol-
lows. Mucosal lesion-lifting using 0.4% SH was steep in
75% of 40 patients and the frequency of bleeding, perfo-
ration, and other intraoperative accidental events was
only 10%. Mild bleeding was encountered in three
patients, and perforation occurred in one. Mucosal resec-
tion required 6.7 (± 14.3) min for completion. The vol-
ume of 0.4% SH was 6.8 (± 8.1) mL and evaluation for
ease of endoscopic resection with 0.4% SH revealed excel-
lent or good results in 87.5% (35/40). Each of these five
parameters suggests that 0.4% SH simplifies the complex
procedures of colorectal endoscopic resection.
Table 5 shows the relationship between usefulness rate
(primary outcome measure) and neoplasm size (as diam-
eter measured endoscopically). Usefulness rate was 89.5%
(17/19), for neoplasms of 5–10 mm; 76.9% (10/13), for
those of 11–15 mm, and 75.0% (6/8) for those of 16–20
mm. Hence, the usefulness rate was high for 0.4% SH irre-
spective of neoplasm size. Table 5 also shows the relation-
ship between usefulness rate and neoplasm location. The
usefulness rates for 0.4% SH were 0% (0/2) in the cecum,
100% (7/7) in the ascending colon, 80.0% (8/10), in the
transverse colon, 92.9% (13/14) in the sigmoid colon and
71.4% (5/7), in the rectum. Again, the usefulness rate was
high for 0.4% SH, irrespective of neoplasm location.
Adverse events
Adverse events developed in 19 (46.3%) of the 41 patients
who underwent endoscopic resection with 0.4% SH. Only
bleeding in two patients (4.9%) was judged to be poten-
tially related to the use of 0.4% SH. Colorectal bleeding 1
day after endoscopic resection at the same site was
resolved completely within the date of onset in the first
patient. In the other patient, the symptom disappeared
the next day from the onset and bleeding did not recur
thereafter. One patient had a perforation, but it was
judged to be unrelated to 0.4% SH. This perforation
occurred accidentally during the management of hemos-
tasis after endoscopic resection and was resolved by endo-
scopic treatment involving only clipping. This perforation
was not caused by injection solution or endoscopic resec-
tion. All other adverse events were judged to be unrelated
to submucosal injection solutions (Table 6). The fre-
quency of serious adverse events, those that prolonged
hospital stay or required hospitalization during therapy
was 9.8% (4/41). These events were two cases of bleeding,
one case of abdominal pain, and one case of perforation
(described above). No events led to death, life-threatening
conditions or notable disabilities. No patient discontin-
ued this study due to adverse events.
Table 2: Demographic characteristics of the 40 patients at 
baseline
Characteristic (n = 40)
Age (years)
Median 64.0
Range 45 – 80
Sex [n (%)]
Male 27 (67.5)
Female 13 (32.5)
Location of neoplasm [n (%)]
Cecum 2 (5.0)
Ascending colon 7 (17.5)
Transverse colon 10 (25.0)
Descending colon 0 (0.0)
Sigmoid colon 14 (35.0)
Rectum 7 (17.5)
Macroscopic classification † [n (%)]
I p 5 (12.5)
I sp 10 (25.0)
I s 4 (10.0)
II a 12 (30.0)
Laterally spreading tumor 8 (20.0)
Other 1 (2.5)
Neoplasm size [n (%)]
5–10 mm 19 (47.5)
11–15 mm 13 (32.5)
16–20 mm 8 (20.0)
† In this trial, we classified neoplasms by the General Rules for Clinical 
and Pathological Studies on Cancer of the Colon, Rectum and Anus 
edited by the Japanese Society for Cancer of the Colon and Rectum. 
This macroscopic classification defines the following as the sub-
superficial types. Ip: pedunculated type; Isp: semipedunculated type; Is: 
sessile type; IIa: superficial elevated type.BMC Gastroenterology 2009, 9:1 http://www.biomedcentral.com/1471-230X/9/1
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Laboratory investigations and vital signs
Total protein, total bilirubin, and blood urea nitrogen lev-
els did not significantly change between the time before
endoscopic resection and 1 or 7 days after endoscopic
resection using 0.4% SH. No abnormal changes in clinical
laboratory findings were correlated with 0.4% SH. No
abnormal changes in vital signs were seen in any of the
patients.
Trial profile Figure 1
Trial profile. Informed consent was obtained from 44 patients. Two patients withdrew informed consent before endoscopic 
resection. One patient did not have a target neoplasm that was defined in our clinical protocol. Therefore, the final number of 
patients who underwent endoscopic resection using 0.4% sodium hyaluronate (SH) was 41. In addition, regarding the histopa-
thology of the multifragment resection, if the histopathological judgment was "vertical and lateral negative margins'', then resec-
tion was considered complete. *1: One patient met the exclusion criteria. *2: En bloc resection with histopathologically 
negative resection margin. *3: A patient had another neoplasm that was in need of treatment.BMC Gastroenterology 2009, 9:1 http://www.biomedcentral.com/1471-230X/9/1
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Endoscopy
At 8 weeks after endoscopic resection, residual neoplastic
tissues or recurrent neoplasms were not evident in any of
the patients. The rate of healing (complete loss of white
patches at the site of resection at 8 weeks after endoscopic
resection) associated with 0.4% SH was 100% (40/40).
Safety and usefulness
Usefulness (primary outcome measure) was assessed in
terms of en bloc complete resection and requirement for
0–1 additional injection, and resection was considered
safe if no adverse events were determined to be related to
submucosal injections and no events led to notable disa-
bility or the requirement of additional treatment. Com-
prehensive assessment of usefulness and safety revealed
that the usefulness rate with a 95% confidence interval for
0.4% SH was 82.5% (33/40; 67.2–92.7%).
Discussion
In colorectal EMR, endoscopists have to acquire the skills
of endoscopic technique, submucosal injection, and snar-
ing because the large intestine has anatomical curves and
Table 3: Treatment methods and the results on 
histopathological diagnosis
Patients (n = 40)
Treatment methods†
Conventional EMR 31 (77.5)
EMR with mucosal incision 3 (7.5)
ESD 6 (15.0)
Depth of invasion
mucosa 40 (100)
submucosa 0 (0.0)
Histological type
adenoma 32 (80.0)
adenocarcinoma
well differentiated adenocarcinoma (wel) 6 (15.0)
moderately differentiated adenocarcinoma (mod) 0 (0.0)
poorly differentiated adenocarcinoma (por) 0 (0.0)
other‡ 2 (5.0)
† Conventional endoscopic mucosal resection (EMR) only to snare 
lesion. EMR with mucosal incision is performed to incise the mucosa 
and snare the lesion. Endoscopic submucosal dissection (ESD) is 
performed to incise the mucosa and dissect submucosa.
‡ One patient had a juvenile polyp; the other had a hyperplastic polyp.
Table 4: Summary of results
Patients (n = 40)
Primary outcome measure
Usefulness rate % (n) 82.5†(33)
Complete en bloc resection 82.5 (33)
Additional counts of injection
none 97.5 (39)
1 0.0 (0)
2 2.5 (1)
Secondary outcome measures
Steepness of mucosal lesion-lifting % (n)
steep 75.0 (30)
mild 22.5 (9)
non-lifted 0.0 (0)
not evaluable 2.5 (1)
Intraoperative accidental events % (n) 10.0 (4)
Ease of mucosal resection % (n)
excellent 62.5 (25)
good 25.0 (10)
moderate 5.0 (2)
poor 7.5 (3)
Time required for mucosal resection (min)
Mean (SD) 6.7 (14.3)
Injection volume (mL)
Mean (SD) 6.8 (8.1)
† 95% confidence interval: 67.2–92.7
Table 5: Usefulness rate for neoplasm size and location
Size
≤ 10 89.5% (17/19)
11–15 76.9% (10/13)
16–20 75.0% (6/8)
Tumor location
Cecum 0% (0/2)
Ascending colon 100% (7/7)
Transverse colon 80.0% (8/10)
Sigmoid colon 92.9% (13/14)
Rectum 71.4% (5/7)
Usefulness rate was defined as the percentage of en bloc complete 
resection that required one additional injection or none.
Table 6: Adverse events
All Patients (n = 41) patients
Patients with adverse events 19 [4] (2)
Adverse events occurring in ≥ 2 patients†
Abdominal pain 4 [1] (0)
Post procedural haemorrhage‡ 4[ 2 ] ( 2 )
Haemorrhage during procedure‡ 3[ 0 ] ( 0 )
Vomiting 2 [0] (0)
Diarrhoea 2 [0] (0)
Insomnia 2 [0] (0)
Intestinal perforation 1 [1] (0)
All patients who had used 0.4% sodium hyaluronate (SH) were 
analyzed for adverse events. The square bracket shows the number of 
patients with serious adverse events. The parenthesis shows the 
number of patients with adverse events that were judged to be 
related to 0.4% SH.
† Although one patient experienced intestinal perforation, this event 
was defined to be a serious adverse event. Therefore, it was added in 
this table.
‡ Bleeding was defined as the use of clipping or another treatment to 
stop or prevent bleeding as well as the incidence of actual bleeding.BMC Gastroenterology 2009, 9:1 http://www.biomedcentral.com/1471-230X/9/1
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many plicae. Endoscopists often could not adequately lift
lesions and maintain those lifted lesions during conven-
tional colorectal EMR using saline, which led to addi-
tional injections, failed snaring and/or perforation
[19,20]. Incomplete resection leads to residual or recur-
rent tumors. Complications of EMR such as bleeding and
perforation often result in a longer hospital stay and
increased hospital costs. Therefore, the mucosal lesion-
lifting method allows easy removal of tumors during
endoscopic resection, leads to en bloc resection, and
decreases complications. Some experimental studies
[19,21] and case reports [13] have described the effective-
ness of SH for EMR. SH is a macromolecular polysaccha-
ride composed of D-glucuronate and N-acetyl-D-
glucosamine; it is ubiquitous in human connective tissues
and body fluids. SH is physicochemically very water reten-
tive and viscoelastic, and is thus clinically used as a safe
intraarticular injection preparation (ARTZ and ARTZ
Dispo, Seikagaku, Tokyo, Japan) or as auxiliary com-
pound in cataract surgery (OPEGAN 1.1 and OPEGAN Hi,
Seikagaku). Because SH is highly viscoelastic even at con-
centrations of ≤ 1%, it does not increase osmotic pressure
and it is not histotoxic [4,19]. Hyun et al described that
mucosal elevation lasted longer with 0.1% SH than with
normal saline in their study using fresh mongrel trans-
verse colon, and this seemed to be due to the viscosity of
the SH solution [20]. However, no multicenter studies
have prospectively investigated the usefulness and safety
of 0.4% SH as a submucosal injection solution in EMR for
colorectal tumors.
We selected 0.4% SH in this study, because Onaya et al
[22] reported that 0.4% SH created higher protrusion than
physiological saline, 50% dextrose, hypertonic saline
(3.7% NaCl), and glycerol. In addition, histological anal-
ysis showed no tissue injury caused by hypertonicity after
0.4% SH use [22]. In this study, we allowed epinephrine
and indigo carmine to be added to submucosal injection
solutions. We did not investigate the potential effect of the
volumes of indigo carmine and epinephrine because we
used such small amounts of these solutions. Therefore, we
believe that additional indigo carmine and epinephrine
had an insignificant effect on the final concentration of
SH.
The intention of calculating a sample size of 35 patients
was to keep the length (precision) of the confidence inter-
val to ± 10% from the success rate when the anticipated en
bloc resection rate was assumed to be 90%. The en bloc
resection rate for the current study was 92.5% (37/40),
and this rate was consistent with our assumption (Figure
1). The en bloc complete resection rate was high (82.5%)
in this study. In 33 (82.5%) patients, submucosal injec-
tion of 0.4% SH was judged to be useful. We had already
reported a prospective multicenter randomized controlled
study describing that the usefulness rate of 0.4% SH for
treating gastric tumors was significantly higher for the
0.4% SH group (88.4%; 61/69) than for the control group
(58.6%; 41/70) (p < 0.001) [6]. The usefulness rate of this
study of colorectal tumors was nearly as high as that of the
gastric tumor study. Uraoka et al reported the en bloc com-
plete resection rate of 62.0% using glycerol and 34.8%
using saline for laterally spreading tumors with size less
than 20 mm [23]. In light of such reported findings, we
believe that the complete en bloc resection rate of 82.5%
found in this study is fairly good from a clinical point of
view. Although the cost of 0.4% SH is higher than that of
saline or glycerol, using 0.4% SH in colorectal endoscopic
resection may lead to a higher en bloc complete resection
rate. In cases of complete resection, patients are generally
followed up on a yearly basis. In contrast, incomplete
resection leads to residual or recurrent tumor and patients
need follow-up endoscopy several times in a year. Thus,
incomplete resection leads to increased medical expenses.
Using SH in endoscopic resection can be expected to
decrease medical expenses for patients and healthcare sys-
tems indirectly by potentially reducing the number of
hospital visits and follow-up cost.
A steep lift was judged to be adequate in 75.0% of 40
patients in this study and 97.5% of 40 patients required
no additional injections for endoscopic resection. No per-
foration occurred due to endoscopic resection in this
study, although one perforation occurred during the man-
agement of bleeding. A solution of 0.4% SH, which is
highly viscoelastic, provided sufficient formation and
maintenance of lifted lesions, prevented perforation and
facilitated safer and more complete procedures. These
findings lead us to believe that 0.4% SH is useful for the
resection of colorectal mucosal lesions.
Adverse events appeared to be at a relatively high rate
(46.3%) in this study because we collected all minor
adverse events in strict compliance with GCP. Major
complications were bleeding during endoscopic resec-
tion (7.3% (3/41)) and postoperative bleeding (9.7%
(4/41)) (Table 6). The adverse event rates in our study
are only slightly higher than the adverse event rates
reported by Uraoka et al [23] regarding the bleeding
during endoscopic resection (0.9% for glycerol and
7.0% for saline) and the postoperative bleeding (6.4%
for glycerol and 4.4% for saline). The slightly elevated
bleeding rates in our study are thought to be unrelated
to the use of SH and to be comparable to the bleeding
rates reported in Uraoka et al.'s study using glycerol
and saline [23]. Nonetheless, it should be kept in
mind that because unexpected bleeding may occur
during colorectal endoscopic resection and such
bleeding is very hard to predict in advance, one should
pay careful attention to the possibility of bleeding
during endoscopic resection using 0.4% SH as well as
other injection solutions.BMC Gastroenterology 2009, 9:1 http://www.biomedcentral.com/1471-230X/9/1
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It must be noted that all procedures in this study were
conducted by highly skilled endoscopists familiar with
colorectal endoscopic resection whereas in other clinical
settings, inexperienced endoscopists might perform color-
ectal endoscopic resections. Insufficient formation and
the inability to maintain lifted lesions seemed to increase
the difficulties associated with procedures. A solution of
0.4% SH could adequately lift and maintain lesions
regardless of lesion location and the risk of perforation
was reduced by creating sufficient space between the mus-
cle layer and the mucosal lesion. In addition, due to its
high molecular weight, 0.4% SH is sufficiently viscoelastic
at low concentrations, does not affect osmotic pressure
and is not associated with tissue damage. These properties
may confer advantages as a local injection solution in
colorectal endoscopic resection.
This study is a prospective open-label study. Although the
study had only a single-arm, a modest sample size and
some subjective measurements as potential limitations,
the findings of the current study shed light on the useful-
ness of 0.4% SH as an aid for surgery when compared with
available historical control data and reported findings
from studies making use of other agents as surgical aids.
Conclusion
The outcomes in this study suggest that 0.4% SH, which
can lift and maintain lesions during resection, can be
applied to colorectal endoscopic resection for enhancing
the ease and safety of the procedures. The potentially
superior safety profile of 0.4% SH supports its use as a
promising submucosal injection solution in place of con-
ventional saline solution.
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